Dyax and ICOS Enter Into License Agreement for Discovery of Therapeutic Antibodies
News May 23, 2006
Under the terms of the agreement, Dyax receives technology license fees from ICOS, as well as clinical milestone payments and royalties on net sales of any products that may result from ICOS's use of the Dyax libraries.
The agreement provides ICOS with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.
Henry E. Blair, Chairman and Chief Executive Officer of Dyax commented, "I'm pleased with the industry recognition of the value of our antibody technology and the sustained growth in Dyax's revenue-generating collaborations, as evidenced by this addition of ICOS to our long list of licensees."
"This arrangement will allow ICOS to utilize Dyax's state-of-the-art libraries of fully human monoclonal antibodies. We look forward to working with the talented team at ICOS, and to potential products moving forward under this license."
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE
Ataxin Links Long Term-Memory and NeurodegenerationNews
Scientists have just discovered that a small region of a cellular protein that helps long-term memories form also drives the neurodegeneration seen in motor neuron disease (MND)READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018